O.L.Vrouw van Troost

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Amyloidosis3 trials
• Stroke3 trials
• Atrial fibrillation2 trials
• Heart failure2 trials
• Coronary artery disease1 trial
• Obesity1 trial
• Peripheral artery disease1 trial

Phase

• Phase 310 trials

Status

• Completed4 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Alnylam Pharmaceuticals Inc.2 trials
• Janssen Research & Development, LLC2 trials
• Alnylam Pharmaceuticals1 trial
• Amgen1 trial
• Amgen Inc.1 trial
• and 3 more

Running trials

• Recruiting

  Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

  NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518343-38-00· Phase 3· Alnylam Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Amyloidosis1 recruiting
• Obesity1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Active, not recruiting

  A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518318-25-00· Phase 3· Alnylam Pharmaceuticals Inc.· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source